Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting

References

• Scheen AJ, Paquot N, Lefebvre PJ. [United Kingdom Prospective Diabetes Study (UKPDS): 10 years later]. Rev Med Liege 2008; 63: 624–629
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1988; 352: 854–865
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, et al. Is glycaemic control improving in U.S. adults?. Diabetes Care 2008; 31: 81–86
   PubMed Web of Science ®Google Scholar
• Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM 2000; 93: 369–374
   PubMed Web of Science ®Google Scholar
• Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev 2002; 18: S42–49
   PubMed Web of Science ®Google Scholar
• Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract 2008; 62: 860–868
   PubMed Web of Science ®Google Scholar
• Crasto W, Jarvis J, Khunti K, et al. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J 2009; 85: 257–267
   Google Scholar
• Hirsch IB, Vega CP. Optimal initiation of insulin in type 2 diabetes. MedGenMed 2005; 7: 49
   PubMedGoogle Scholar
• Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycaemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25: 883–888
   PubMed Web of Science ®Google Scholar
• Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med 2002; 19: 393–399
   PubMed Web of Science ®Google Scholar
• Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008; 149: 549–559
   PubMed Web of Science ®Google Scholar
• Coscelli C, Calabrese G, Fedele D, et al. Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care 1992; 15: 1628–1630
   PubMed Web of Science ®Google Scholar
• Bell DS, Clements RS, Jr, Perentesis G, et al. Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med 1991; 151: 2265–2269
   PubMed Web of Science ®Google Scholar
• Majumdar S, Barrett E. Newer insulins in search of a niche. Ann Intern Med 2008; 149: 586–588
   PubMed Web of Science ®Google Scholar
• Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human?. Diabetes Obes Metab 2007; 9: 630–639
   PubMed Web of Science ®Google Scholar
• Ligthelm RJ, Borzi V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin Ther 2007; 29: 1284–1292
   Web of Science ®Google Scholar
• Valensi P, Benroubi M, Borzi V, et al. The IMPROVE study–a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008; 62: 1809–1819
   PubMed Web of Science ®Google Scholar
• Valensi P, Benroubi M, Borzi V, et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009; 63: 522–531
   PubMed Web of Science ®Google Scholar
• Gumprecht J, Benroubi M, Borzi V, et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009; 63: 966–972
   PubMed Web of Science ®Google Scholar
• Shah S, Benroubi M, Borzi V, et al. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract 2009; 63: 574–582
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20: S27–40
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004; 20: S5–S26
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559
   PubMed Web of Science ®Google Scholar
• Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18: 2644–2648
   PubMed Web of Science ®Google Scholar
• Minshall ME, Oglesby AK, Wintle ME, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008; 11: 22–33
   PubMed Web of Science ®Google Scholar
• Tarn TSM. Pharmacoeconomic Guidelines Around the World. ISPOR Connections 2004; 10: 5–15
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ–5D (UKPDS 62). Med Decis Making 2002; 22: 340–349
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. The Burden of Disease and Injury in Australia 2003. Available at http://www.aihw.gov.au/. Accessed January 2009.
   Google Scholar
• Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38: 583–637
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22: 1523–1534
   PubMed Web of Science ®Google Scholar
• Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327–340
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25: 245–254
   PubMed Web of Science ®Google Scholar
• Boehm BO, Vaz JA, Brøndsted L, et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004; 15: 496–502
   PubMedGoogle Scholar
• Breum L, Almdal T, Lund P, et al. Initiating or switching to biphasic insulin aspart 30/70 therapy in subjects with type 2 diabetes mellitus. An observational study. Rev Diabet Stud 2008; 5: 154–162
   PubMedGoogle Scholar
• Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008; 6: 73
   PubMed Web of Science ®Google Scholar
• Klarenbach SW, Jacobs P. International comparison of health resource utilization in subjects with diabetes: an analysis of Canadian and American national health surveys. Diabetes Care 2003; 26: 1116–1122
   PubMed Web of Science ®Google Scholar
• Booth GL, Zinman B, Redelmeier DA. Diabetes care in the U.S. and Canada. Diabetes Care 2002; 25: 1149–1153
   PubMed Web of Science ®Google Scholar
• Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003; 26: 2300–2304
   PubMed Web of Science ®Google Scholar